344 related articles for article (PubMed ID: 23264597)
21. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
22. Targeting Signaling Pathways in Chronic Lymphocytic Leukemia.
Muggen AF; Singh SP; Hendriks RW; Langerak AW
Curr Cancer Drug Targets; 2016; 16(8):669-688. PubMed ID: 27055580
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
24. Signal transduction inhibitors in chronic lymphocytic leukemia.
Ma S; Rosen ST
Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
[TBL] [Abstract][Full Text] [Related]
25. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2012; 2012():88-96. PubMed ID: 23233565
[TBL] [Abstract][Full Text] [Related]
26. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
27. Rho and Rap guanosine triphosphatase signaling in B cells and chronic lymphocytic leukemia.
Mele S; Devereux S; Ridley AJ
Leuk Lymphoma; 2014 Sep; 55(9):1993-2001. PubMed ID: 24237579
[TBL] [Abstract][Full Text] [Related]
28. The B-cell receptor signaling pathway as a therapeutic target in CLL.
Woyach JA; Johnson AJ; Byrd JC
Blood; 2012 Aug; 120(6):1175-84. PubMed ID: 22715122
[TBL] [Abstract][Full Text] [Related]
29. [Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
Mráz M; Doubek M; Mayer J
Klin Onkol; 2013; 26(3):179-85. PubMed ID: 23763320
[TBL] [Abstract][Full Text] [Related]
30. [Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].
Ji TT; Chen QN; Tao SD; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):708-712. PubMed ID: 32319422
[TBL] [Abstract][Full Text] [Related]
31. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
32. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
33. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia.
Burger JA
Hematology Am Soc Hematol Educ Program; 2011; 2011():96-103. PubMed ID: 22160019
[TBL] [Abstract][Full Text] [Related]
34. How will B-cell-receptor-targeted therapies change future CLL therapy?
Jones JA; Byrd JC
Blood; 2014 Mar; 123(10):1455-60. PubMed ID: 24394667
[TBL] [Abstract][Full Text] [Related]
35. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Seda V; Mraz M
Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
[TBL] [Abstract][Full Text] [Related]
36. [Targeted treatment of chronic lymphocytic leukaemia].
Niemann CU
Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
[TBL] [Abstract][Full Text] [Related]
37. GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia.
Macias-Perez IM; Flinn IW
Curr Hematol Malig Rep; 2013 Mar; 8(1):22-7. PubMed ID: 23114654
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.
Herman SE; Niemann CU; Farooqui M; Jones J; Mustafa RZ; Lipsky A; Saba N; Martyr S; Soto S; Valdez J; Gyamfi JA; Maric I; Calvo KR; Pedersen LB; Geisler CH; Liu D; Marti GE; Aue G; Wiestner A
Leukemia; 2014 Nov; 28(11):2188-96. PubMed ID: 24699307
[TBL] [Abstract][Full Text] [Related]
39. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Hoellenriegel J; Coffey GP; Sinha U; Pandey A; Sivina M; Ferrajoli A; Ravandi F; Wierda WG; O'Brien S; Keating MJ; Burger JA
Leukemia; 2012 Jul; 26(7):1576-83. PubMed ID: 22362000
[TBL] [Abstract][Full Text] [Related]
40. Critical molecular pathways in CLL therapy.
Ferrer G; Montserrat E
Mol Med; 2018 Mar; 24(1):9. PubMed ID: 30134797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]